Research May Lend Support To Xarelto Lawsuit Claims

July 05, 2016 – – TheProductLawyers.com reports on research that may lend credibility to claims against Xarelto and its manufacturers, Bayer AG and Janssen Pharmaceuticals (a Johnson & Johnson subsidiary). A suggested link between the heightened risk for catastrophic hemorrhages and the new-generation blood thinner prompts concern from the public and medical circles.

In 2011, the FDA granted approval to Xarelto. Its intended uses—clot prevention in patients with pulmonary embolism or deep vein thrombosis and those recuperating from knee or hip replacement surgeries—were expanded to include stroke prevention in patients with atrial fibrillation. At first, the new-generation anticoagulant was hailed as a breakthrough in clot prevention techniques and was warmly received.

However, growing numbers of adverse event reports alleging a link between the drug and pulmonary embolism, clots, strokes, and uncontrollable internal and external hemorrhages soon caused concern among some in the medical community. Drs. John C. Hwang and Judy H. Hun conducted a preliminary study among patients in their own practice who had begun a Xarelto regimen. They found that at least three of those included had suffered from “spontaneous vitreous hemorrhage” or eye bleeding. The doctors noted that the risk for these bleeding events was most pronounced in those who had switched to Xarelto after using more traditional anticoagulants.

The second study, which was longer in duration and incorporated patient data from across the U.S., studied comparative risk profiles of those using various anticoagulant drugs. Compiling more than 46,000 relevant patient histories—39,607 warfarin; 4,907 Pradaxa; 1,649 Xarelto—the data indicated a specific trend. Researchers noted that there was “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”

The U.S. Judicial Panel on Multidistrict Litigation combined more than 2,800 cases with similar claims alleging a link between elevated risk and use of Xarelto. Cases in multidistrict litigation (MDL) 2592 will be tried in the Eastern District of Louisiana under Judge Eldon Fallon. As the cases await court dates, any subsequent lawsuits with similar allegations will be incorporated into the MDL.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011202